A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Authors

Institutions

Publication Details

Journal
American Journal of Obstetrics and Gynecology
Published
2025-08-05
DOI
https://doi.org/10.1016/j.ajog.2025.07.040
Citations
7
Primary Topic
Reproductive tract infections research
Type
article
Field-Weighted Citation Impact
8.28
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Nkechi Azie, Paul Nyirjesy, Ryan Sobel, Oluwatosin Goje et al.
7 citations
American Journal of Obstetrics and Gynecology
Reproductive tract infections research
8.28
article

A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Nkechi Azie, Paul Nyirjesy, Ryan Sobel, Oluwatosin Goje, Jack D. Sobel, David Angulo
article en
7 citations

Abstract

No abstract available for this paper.
American Journal of Obstetrics and GynecologyVol. 233(6)
Cleveland Clinic (US), Thomas Jefferson University (US), Wayne State University (US), Cleveland Foundation (US), Scynexis (United States) (US)
Good health and well-being
Openalex Percentile: Top 2%
Reproductive tract infections research
8.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.